Craft

Repros Therapeutics

Revenue

$47 K

FY, 2016

Repros Therapeutics Summary

Company Summary

Overview
Repros Therapeutics is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis; enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor.
Type
Subsidiary
Status
Closed
Founded
1987
HQ
Houston, TX, US | view all locations
Website
http://www.reprosrx.com/
Cybersecurity rating
Sectors

LocationsView all

1 location detected

  • Houston, TX HQ

    United States

    2408 Timberloch Place, B-7

Repros Therapeutics Financials

Summary Financials

Revenue (Q3, 2017)
$304.0K
Net income (Q3, 2017)
($1.6M)
Cash (Q3, 2017)
$1.8M

Footer menu